Natco Pharma is currently trading at Rs. 913.45, up by 15.40 points or 1.71% from its previous closing of Rs. 898.05 on the BSE.
The scrip opened at Rs. 910.00 and has touched a high and low of Rs. 920.80 and Rs. 909.60 respectively. So far 68718 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1015.00 on 18-Apr-2017 and a 52 week low of Rs. 440.00 on 11-May-2016.
Last one week high and low of the scrip stood at Rs. 923.50 and Rs. 883.00 respectively. The current market cap of the company is Rs. 15909.07 crore.
The promoters holding in the company stood at 51.24%, while Institutions and Non-Institutions held 26.70% and 22.05% respectively.
Natco Pharma has launched a generic version of pomalidomide 1 mg, 2 mg, and 4 mg capsules in India. Pomalidomide is sold by Celgene Inc., in the USA, under the brand name ‘Pomalyst’.
Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Natco will market generic pomalidomide capsules under its brand name POMALID in India. Natco priced its generic medicine of POMALID 1 mg, 2 mg, and 4 mg capsules at an MRP of Rs 5000, Rs 10,000 and Rs 20,000 respectively for a monthly pack of 21 capsules.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: